Moderna, Inc. (MRNA) Stock Competitors & Peer Comparison
See (MRNA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRNA | $68.28 | +1.25% | 27.1B | -8.38 | -$8.15 | N/A |
| VRTX | $477.08 | +0.16% | 121.1B | 25.35 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $664.45 | +1.27% | 68.5B | 14.56 | $45.63 | +0.55% |
| ARGX | $862.93 | +0.41% | 54B | 77.88 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.08 | +1.11% | 39.7B | -2.19 | -$4.15 | N/A |
| RVMD | $184.44 | -0.29% | 39.2B | -26.09 | -$7.07 | N/A |
| ALNY | $279.14 | -0.75% | 37.3B | 50.30 | $5.55 | N/A |
| ONC | $311.26 | +1.53% | 33.3B | 69.63 | $4.47 | N/A |
Stock Comparison
MRNA vs VRTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, MRNA is priced at $68.28, while VRTX trades at $477.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas VRTX's P/E ratio is 25.35. In terms of profitability, MRNA's ROE is -0.37%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, MRNA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VRTX's competition here
MRNA vs VRNA Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MRNA is priced at $68.28, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MRNA's ROE is -0.37%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, MRNA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VRNA's competition here
MRNA vs REGN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, REGN has a market cap of 68.5B. Regarding current trading prices, MRNA is priced at $68.28, while REGN trades at $664.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas REGN's P/E ratio is 14.56. In terms of profitability, MRNA's ROE is -0.37%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MRNA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check REGN's competition here
MRNA vs ARGX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ARGX has a market cap of 54B. Regarding current trading prices, MRNA is priced at $68.28, while ARGX trades at $862.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ARGX's P/E ratio is 77.88. In terms of profitability, MRNA's ROE is -0.37%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, MRNA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ARGX's competition here
MRNA vs SGEN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MRNA is priced at $68.28, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MRNA's ROE is -0.37%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MRNA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SGEN's competition here
MRNA vs RVMDW Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, RVMDW has a market cap of 39.7B. Regarding current trading prices, MRNA is priced at $68.28, while RVMDW trades at $9.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas RVMDW's P/E ratio is -2.19. In terms of profitability, MRNA's ROE is -0.37%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, MRNA is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check RVMDW's competition here
MRNA vs RVMD Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, RVMD has a market cap of 39.2B. Regarding current trading prices, MRNA is priced at $68.28, while RVMD trades at $184.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas RVMD's P/E ratio is -26.09. In terms of profitability, MRNA's ROE is -0.37%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, MRNA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RVMD's competition here
MRNA vs ALNY Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ALNY has a market cap of 37.3B. Regarding current trading prices, MRNA is priced at $68.28, while ALNY trades at $279.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ALNY's P/E ratio is 50.30. In terms of profitability, MRNA's ROE is -0.37%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, MRNA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALNY's competition here
MRNA vs ONC Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ONC has a market cap of 33.3B. Regarding current trading prices, MRNA is priced at $68.28, while ONC trades at $311.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ONC's P/E ratio is 69.63. In terms of profitability, MRNA's ROE is -0.37%, compared to ONC's ROE of +0.12%. Regarding short-term risk, MRNA is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ONC's competition here
MRNA vs ROIV Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ROIV has a market cap of 25.1B. Regarding current trading prices, MRNA is priced at $68.28, while ROIV trades at $34.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ROIV's P/E ratio is -35.86. In terms of profitability, MRNA's ROE is -0.37%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, MRNA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ROIV's competition here
MRNA vs INSM Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, INSM has a market cap of 23.8B. Regarding current trading prices, MRNA is priced at $68.28, while INSM trades at $109.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas INSM's P/E ratio is -19.10. In terms of profitability, MRNA's ROE is -0.37%, compared to INSM's ROE of -1.30%. Regarding short-term risk, MRNA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check INSM's competition here
MRNA vs BNTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, MRNA is priced at $68.28, while BNTX trades at $91.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas BNTX's P/E ratio is -19.91. In terms of profitability, MRNA's ROE is -0.37%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, MRNA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BNTX's competition here
MRNA vs INCY Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, INCY has a market cap of 23B. Regarding current trading prices, MRNA is priced at $68.28, while INCY trades at $115.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas INCY's P/E ratio is 15.47. In terms of profitability, MRNA's ROE is -0.37%, compared to INCY's ROE of +0.29%. Regarding short-term risk, MRNA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check INCY's competition here
MRNA vs UTHR Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, UTHR has a market cap of 22.6B. Regarding current trading prices, MRNA is priced at $68.28, while UTHR trades at $531.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas UTHR's P/E ratio is 19.63. In terms of profitability, MRNA's ROE is -0.37%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MRNA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check UTHR's competition here
MRNA vs BGNE Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MRNA is priced at $68.28, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MRNA's ROE is -0.37%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, MRNA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BGNE's competition here
MRNA vs DNA-WT Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MRNA is priced at $68.28, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.37%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, MRNA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check DNA-WT's competition here
MRNA vs GMAB Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, GMAB has a market cap of 17.9B. Regarding current trading prices, MRNA is priced at $68.28, while GMAB trades at $29.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas GMAB's P/E ratio is 20.92. In terms of profitability, MRNA's ROE is -0.37%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, MRNA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check GMAB's competition here
MRNA vs NBIX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, NBIX has a market cap of 17.3B. Regarding current trading prices, MRNA is priced at $68.28, while NBIX trades at $171.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas NBIX's P/E ratio is 24.84. In terms of profitability, MRNA's ROE is -0.37%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, MRNA is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NBIX's competition here
MRNA vs ASND Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ASND has a market cap of 16.7B. Regarding current trading prices, MRNA is priced at $68.28, while ASND trades at $268.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ASND's P/E ratio is -110.98. In terms of profitability, MRNA's ROE is -0.37%, compared to ASND's ROE of -56.42%. Regarding short-term risk, MRNA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ASND's competition here
MRNA vs BBIO Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, BBIO has a market cap of 16.2B. Regarding current trading prices, MRNA is priced at $68.28, while BBIO trades at $82.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas BBIO's P/E ratio is -22.10. In terms of profitability, MRNA's ROE is -0.37%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, MRNA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BBIO's competition here
MRNA vs JAZZ Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, MRNA is priced at $68.28, while JAZZ trades at $239.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas JAZZ's P/E ratio is 18.61. In terms of profitability, MRNA's ROE is -0.37%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, MRNA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check JAZZ's competition here
MRNA vs EXEL Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, MRNA is priced at $68.28, while EXEL trades at $55.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas EXEL's P/E ratio is 16.63. In terms of profitability, MRNA's ROE is -0.37%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, MRNA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check EXEL's competition here
MRNA vs MDGL Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, MRNA is priced at $68.28, while MDGL trades at $550.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas MDGL's P/E ratio is -42.99. In terms of profitability, MRNA's ROE is -0.37%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, MRNA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check MDGL's competition here
MRNA vs KRTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MRNA is priced at $68.28, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MRNA's ROE is -0.37%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MRNA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check KRTX's competition here
MRNA vs AXSM Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, AXSM has a market cap of 12.2B. Regarding current trading prices, MRNA is priced at $68.28, while AXSM trades at $237.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas AXSM's P/E ratio is -62.02. In terms of profitability, MRNA's ROE is -0.37%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, MRNA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check AXSM's competition here
MRNA vs SMMT Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, SMMT has a market cap of 11.7B. Regarding current trading prices, MRNA is priced at $68.28, while SMMT trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas SMMT's P/E ratio is -9.42. In terms of profitability, MRNA's ROE is -0.37%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, MRNA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check SMMT's competition here
MRNA vs BMRN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, MRNA is priced at $68.28, while BMRN trades at $58.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas BMRN's P/E ratio is 28.34. In terms of profitability, MRNA's ROE is -0.37%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, MRNA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BMRN's competition here
MRNA vs RNAM Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MRNA is priced at $68.28, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MRNA's ROE is -0.37%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MRNA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RNAM's competition here
MRNA vs TECH Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, MRNA is priced at $68.28, while TECH trades at $71.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas TECH's P/E ratio is 36.85. In terms of profitability, MRNA's ROE is -0.37%, compared to TECH's ROE of +0.05%. Regarding short-term risk, MRNA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TECH's competition here
MRNA vs KRYS Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, KRYS has a market cap of 10.3B. Regarding current trading prices, MRNA is priced at $68.28, while KRYS trades at $350.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas KRYS's P/E ratio is 46.82. In terms of profitability, MRNA's ROE is -0.37%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MRNA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check KRYS's competition here
MRNA vs CYTK Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CYTK has a market cap of 10.3B. Regarding current trading prices, MRNA is priced at $68.28, while CYTK trades at $82.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CYTK's P/E ratio is -14.17. In terms of profitability, MRNA's ROE is -0.37%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, MRNA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CYTK's competition here
MRNA vs ARWR Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ARWR has a market cap of 10.1B. Regarding current trading prices, MRNA is priced at $68.28, while ARWR trades at $71.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ARWR's P/E ratio is -33.40. In terms of profitability, MRNA's ROE is -0.37%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, MRNA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check ARWR's competition here
MRNA vs ABVX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ABVX has a market cap of 10.1B. Regarding current trading prices, MRNA is priced at $68.28, while ABVX trades at $136.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ABVX's P/E ratio is -71.78. In terms of profitability, MRNA's ROE is -0.37%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MRNA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ABVX's competition here
MRNA vs CORT Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CORT has a market cap of 9.6B. Regarding current trading prices, MRNA is priced at $68.28, while CORT trades at $89.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CORT's P/E ratio is 255.91. In terms of profitability, MRNA's ROE is -0.37%, compared to CORT's ROE of +0.08%. Regarding short-term risk, MRNA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check CORT's competition here
MRNA vs RXDX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MRNA is priced at $68.28, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MRNA's ROE is -0.37%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RXDX's competition here
MRNA vs KYMR Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, KYMR has a market cap of 9.4B. Regarding current trading prices, MRNA is priced at $68.28, while KYMR trades at $114.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas KYMR's P/E ratio is -32.33. In terms of profitability, MRNA's ROE is -0.37%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, MRNA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check KYMR's competition here
MRNA vs NUVL Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MRNA is priced at $68.28, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas NUVL's P/E ratio is -21.79. In terms of profitability, MRNA's ROE is -0.37%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MRNA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NUVL's competition here
MRNA vs IONS Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, MRNA is priced at $68.28, while IONS trades at $54.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas IONS's P/E ratio is -31.82. In terms of profitability, MRNA's ROE is -0.37%, compared to IONS's ROE of -0.59%. Regarding short-term risk, MRNA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IONS's competition here
MRNA vs HALO Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, HALO has a market cap of 9B. Regarding current trading prices, MRNA is priced at $68.28, while HALO trades at $75.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas HALO's P/E ratio is 16.41. In terms of profitability, MRNA's ROE is -0.37%, compared to HALO's ROE of +1.26%. Regarding short-term risk, MRNA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check HALO's competition here
MRNA vs CRNX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, MRNA is priced at $68.28, while CRNX trades at $83.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CRNX's P/E ratio is -16.35. In terms of profitability, MRNA's ROE is -0.37%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MRNA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CRNX's competition here
MRNA vs IMGN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MRNA is priced at $68.28, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MRNA's ROE is -0.37%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MRNA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check IMGN's competition here
MRNA vs PTGX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, MRNA is priced at $68.28, while PTGX trades at $135.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas PTGX's P/E ratio is -74.84. In terms of profitability, MRNA's ROE is -0.37%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, MRNA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check PTGX's competition here
MRNA vs ALKS Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ALKS has a market cap of 8.7B. Regarding current trading prices, MRNA is priced at $68.28, while ALKS trades at $51.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ALKS's P/E ratio is 54.72. In terms of profitability, MRNA's ROE is -0.37%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, MRNA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALKS's competition here
MRNA vs TGTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, MRNA is priced at $68.28, while TGTX trades at $56.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas TGTX's P/E ratio is 19.38. In terms of profitability, MRNA's ROE is -0.37%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, MRNA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check TGTX's competition here
MRNA vs BPMC Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MRNA is priced at $68.28, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MRNA's ROE is -0.37%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check BPMC's competition here
MRNA vs APGE Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, MRNA is priced at $68.28, while APGE trades at $134.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas APGE's P/E ratio is -31.01. In terms of profitability, MRNA's ROE is -0.37%, compared to APGE's ROE of -0.33%. Regarding short-term risk, MRNA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check APGE's competition here
MRNA vs PCVX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, MRNA is priced at $68.28, while PCVX trades at $56.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas PCVX's P/E ratio is -8.25. In terms of profitability, MRNA's ROE is -0.37%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, MRNA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PCVX's competition here
MRNA vs CERE Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MRNA is priced at $68.28, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CERE's P/E ratio is -16.47. In terms of profitability, MRNA's ROE is -0.37%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MRNA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CERE's competition here
MRNA vs IMVT Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, MRNA is priced at $68.28, while IMVT trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas IMVT's P/E ratio is -14.94. In terms of profitability, MRNA's ROE is -0.37%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, MRNA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check IMVT's competition here
MRNA vs IBRX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, IBRX has a market cap of 8.1B. Regarding current trading prices, MRNA is priced at $68.28, while IBRX trades at $7.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas IBRX's P/E ratio is -9.09. In terms of profitability, MRNA's ROE is -0.37%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, MRNA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check IBRX's competition here
MRNA vs RYTM Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, MRNA is priced at $68.28, while RYTM trades at $109.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas RYTM's P/E ratio is -35.04. In terms of profitability, MRNA's ROE is -0.37%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, MRNA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RYTM's competition here
MRNA vs MTSR Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MRNA is priced at $68.28, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MRNA's ROE is -0.37%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, MRNA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MTSR's competition here
MRNA vs LQDA Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, LQDA has a market cap of 6.9B. Regarding current trading prices, MRNA is priced at $68.28, while LQDA trades at $77.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas LQDA's P/E ratio is 555.36. In terms of profitability, MRNA's ROE is -0.37%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, MRNA is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check LQDA's competition here
MRNA vs MRUS Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MRNA is priced at $68.28, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MRNA's ROE is -0.37%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, MRNA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MRUS's competition here
MRNA vs ACLX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MRNA is priced at $68.28, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MRNA's ROE is -0.37%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MRNA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ACLX's competition here
MRNA vs PRAX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, MRNA is priced at $68.28, while PRAX trades at $318.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas PRAX's P/E ratio is -23.82. In terms of profitability, MRNA's ROE is -0.37%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, MRNA is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PRAX's competition here
MRNA vs COGT Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, MRNA is priced at $68.28, while COGT trades at $39.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas COGT's P/E ratio is -18.63. In terms of profitability, MRNA's ROE is -0.37%, compared to COGT's ROE of -0.83%. Regarding short-term risk, MRNA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check COGT's competition here
MRNA vs ERAS Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $68.28, while ERAS trades at $21.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ERAS's P/E ratio is -48.32. In terms of profitability, MRNA's ROE is -0.37%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, MRNA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check ERAS's competition here
MRNA vs RETA Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $68.28, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas RETA's P/E ratio is -66.29. In terms of profitability, MRNA's ROE is -0.37%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MRNA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RETA's competition here
MRNA vs PTCT Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, MRNA is priced at $68.28, while PTCT trades at $78.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas PTCT's P/E ratio is -33.84. In terms of profitability, MRNA's ROE is -0.37%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, MRNA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check PTCT's competition here
MRNA vs SRRK Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, SRRK has a market cap of 6.5B. Regarding current trading prices, MRNA is priced at $68.28, while SRRK trades at $54.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas SRRK's P/E ratio is -15.05. In terms of profitability, MRNA's ROE is -0.37%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, MRNA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check SRRK's competition here
MRNA vs CGON Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, MRNA is priced at $68.28, while CGON trades at $73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CGON's P/E ratio is -31.33. In terms of profitability, MRNA's ROE is -0.37%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MRNA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check CGON's competition here
MRNA vs CNTA Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, MRNA is priced at $68.28, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CNTA's P/E ratio is -22.63. In terms of profitability, MRNA's ROE is -0.37%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MRNA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CNTA's competition here
MRNA vs SYRE Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, SYRE has a market cap of 6.2B. Regarding current trading prices, MRNA is priced at $68.28, while SYRE trades at $102.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas SYRE's P/E ratio is -49.07. In terms of profitability, MRNA's ROE is -0.37%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, MRNA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check SYRE's competition here
MRNA vs MIRM Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, MRNA is priced at $68.28, while MIRM trades at $121.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas MIRM's P/E ratio is -8.89. In terms of profitability, MRNA's ROE is -0.37%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, MRNA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MIRM's competition here
MRNA vs BLTE Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, MRNA is priced at $68.28, while BLTE trades at $149.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas BLTE's P/E ratio is -79.93. In terms of profitability, MRNA's ROE is -0.37%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, MRNA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check BLTE's competition here
MRNA vs LGND Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, MRNA is priced at $68.28, while LGND trades at $296.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas LGND's P/E ratio is 35.52. In terms of profitability, MRNA's ROE is -0.37%, compared to LGND's ROE of +0.16%. Regarding short-term risk, MRNA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check LGND's competition here
MRNA vs CDTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $68.28, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MRNA's ROE is -0.37%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, MRNA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CDTX's competition here
MRNA vs ABCM Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $68.28, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MRNA's ROE is -0.37%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MRNA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ABCM's competition here
MRNA vs ISEE Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $68.28, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MRNA's ROE is -0.37%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MRNA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ISEE's competition here
MRNA vs XENE Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, XENE has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $68.28, while XENE trades at $67.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas XENE's P/E ratio is -14.41. In terms of profitability, MRNA's ROE is -0.37%, compared to XENE's ROE of -0.49%. Regarding short-term risk, MRNA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check XENE's competition here
MRNA vs TVTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $68.28, while TVTX trades at $56.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas TVTX's P/E ratio is -257.91. In terms of profitability, MRNA's ROE is -0.37%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, MRNA is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TVTX's competition here
MRNA vs APLS Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $68.28, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas APLS's P/E ratio is 38.35. In terms of profitability, MRNA's ROE is -0.37%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MRNA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check APLS's competition here
MRNA vs MANE Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, MANE has a market cap of 5.2B. Regarding current trading prices, MRNA is priced at $68.28, while MANE trades at $123.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas MANE's P/E ratio is -39.39. In terms of profitability, MRNA's ROE is -0.37%, compared to MANE's ROE of -0.84%. Regarding short-term risk, MRNA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check MANE's competition here
MRNA vs DFTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, MRNA is priced at $68.28, while DFTX trades at $45.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas DFTX's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.37%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, MRNA is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check DFTX's competition here
MRNA vs CRSP Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, MRNA is priced at $68.28, while CRSP trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CRSP's P/E ratio is -10.05. In terms of profitability, MRNA's ROE is -0.37%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CRSP's competition here
MRNA vs CAI Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, MRNA is priced at $68.28, while CAI trades at $17.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CAI's P/E ratio is -96.04. In terms of profitability, MRNA's ROE is -0.37%, compared to CAI's ROE of +0.06%. Regarding short-term risk, MRNA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check CAI's competition here
MRNA vs TERN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MRNA is priced at $68.28, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas TERN's P/E ratio is -51.41. In terms of profitability, MRNA's ROE is -0.37%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MRNA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TERN's competition here
MRNA vs FOLD Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $68.28, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MRNA's ROE is -0.37%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MRNA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check FOLD's competition here
MRNA vs AKRO Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $68.28, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MRNA's ROE is -0.37%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, MRNA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check AKRO's competition here
MRNA vs CELC Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $68.28, while CELC trades at $91.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CELC's P/E ratio is -23.46. In terms of profitability, MRNA's ROE is -0.37%, compared to CELC's ROE of -2.45%. Regarding short-term risk, MRNA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check CELC's competition here
MRNA vs ALPN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $68.28, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MRNA's ROE is -0.37%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MRNA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ALPN's competition here
MRNA vs ACAD Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, MRNA is priced at $68.28, while ACAD trades at $25.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ACAD's P/E ratio is 12.71. In terms of profitability, MRNA's ROE is -0.37%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, MRNA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check ACAD's competition here
MRNA vs EWTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, MRNA is priced at $68.28, while EWTX trades at $40.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas EWTX's P/E ratio is -24.60. In terms of profitability, MRNA's ROE is -0.37%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, MRNA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check EWTX's competition here
MRNA vs VKTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, MRNA is priced at $68.28, while VKTX trades at $37.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas VKTX's P/E ratio is -9.13. In terms of profitability, MRNA's ROE is -0.37%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, MRNA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check VKTX's competition here
MRNA vs LEGN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, LEGN has a market cap of 4.3B. Regarding current trading prices, MRNA is priced at $68.28, while LEGN trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas LEGN's P/E ratio is -33.88. In terms of profitability, MRNA's ROE is -0.37%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, MRNA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check LEGN's competition here
MRNA vs OPT Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $68.28, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas OPT's P/E ratio is -1.52. In terms of profitability, MRNA's ROE is -0.37%, compared to OPT's ROE of +1.18%. Regarding short-term risk, MRNA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check OPT's competition here
MRNA vs DNTH Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $68.28, while DNTH trades at $99.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas DNTH's P/E ratio is -24.19. In terms of profitability, MRNA's ROE is -0.37%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, MRNA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check DNTH's competition here
MRNA vs MRTX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MRNA is priced at $68.28, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MRNA's ROE is -0.37%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MRNA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check MRTX's competition here
MRNA vs DYN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, DYN has a market cap of 4B. Regarding current trading prices, MRNA is priced at $68.28, while DYN trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas DYN's P/E ratio is -7.45. In terms of profitability, MRNA's ROE is -0.37%, compared to DYN's ROE of -0.58%. Regarding short-term risk, MRNA is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check DYN's competition here
MRNA vs CPRX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, MRNA is priced at $68.28, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CPRX's P/E ratio is 12.30. In terms of profitability, MRNA's ROE is -0.37%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MRNA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CPRX's competition here
MRNA vs TLX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $68.28, while TLX trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas TLX's P/E ratio is -613.59. In terms of profitability, MRNA's ROE is -0.37%, compared to TLX's ROE of -0.02%. Regarding short-term risk, MRNA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TLX's competition here
MRNA vs NAMSW Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, NAMSW has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $68.28, while NAMSW trades at $20.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas NAMSW's P/E ratio is -11.37. In terms of profitability, MRNA's ROE is -0.37%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, MRNA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check NAMSW's competition here
MRNA vs ELVN Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $68.28, while ELVN trades at $53.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas ELVN's P/E ratio is -31.83. In terms of profitability, MRNA's ROE is -0.37%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, MRNA is less volatile compared to ELVN. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check ELVN's competition here
MRNA vs TNGX Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $68.28, while TNGX trades at $30.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas TNGX's P/E ratio is -36.45. In terms of profitability, MRNA's ROE is -0.37%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, MRNA is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check TNGX's competition here
MRNA vs RYZB Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $68.28, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MRNA's ROE is -0.37%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MRNA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check RYZB's competition here
MRNA vs NAMS Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $68.28, while NAMS trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas NAMS's P/E ratio is -20.11. In terms of profitability, MRNA's ROE is -0.37%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, MRNA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check NAMS's competition here
MRNA vs CBAY Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $68.28, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MRNA's ROE is -0.37%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MRNA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MRNA.Check CBAY's competition here
MRNA vs DNLI Comparison July 2026
MRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 27.1B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $68.28, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -8.38, whereas DNLI's P/E ratio is -7.99. In terms of profitability, MRNA's ROE is -0.37%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, MRNA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for MRNA.Check DNLI's competition here